Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCCR Open-Label Extension in Prader-Willi Syndrome
NCT04086810Phase 3Withdrawn
- Sponsor
- Soleno Therapeutics
- Start
- Oct 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of methylphenidate hydrochloride extended-release chewable tablet in Prader-Willi syndrome (PWS), sponsored by Soleno Therapeutics. Primary endpoint: Adverse Events. Planned start Oct 2019; status: withdrawn.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT04086810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086810.